International evidence base

  1. Zuberbier T, Ansari ZAH, Abdul Latiff AH, et al. The international guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2026;81(8):2582-2632. doi:10.1111/all.70210The umbrella international guideline (2026 revision, per the campaign reference list). Used throughout this site for the 6-week threshold, diagnostic framework, internal-immune mechanism, and step-up treatment algorithm.
  2. Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423-432.Cited for the estimated lifetime prevalence of approximately 1 in 100.
  3. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy. 2011;66(3):317-330.Cited for the patient-reported burden of CSU, treatment limitations, and quality-of-life impact.
  4. O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. British Journal of Dermatology. 1997;136(2):197-201.Foundational quality-of-life paper. Cited where the site discusses sleep, work, and daily-life impact.
  5. Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. Journal of Allergy and Clinical Immunology. 2022;149(6):1819-1831. doi:10.1016/j.jaci.2022.04.010Cited for the autoimmune/internal-immune mechanism underlying CSU in many patients. (Replaces an earlier incomplete Kolkhir 2017 entry; this is the citation on the campaign reference list.)

Regional and Philippine sources

  1. Philippine Dermatological Society (PDS). National accrediting body for board-certified dermatologists in the Philippines. Member directory and clinical practice resources. Available at: pds.org.phCited as the institutional source for board-certification verification and the Find a Doctor pathway. PH-specific clinical guidance and any PDS position papers on CSU will be added during MLR review.
  2. Recto M, Woo K, Chung WH, et al. Prioritising patient-centred care in the management of chronic urticaria in Asia-Pacific countries. World Allergy Organization Journal. 2024;17(11):100984. doi:10.1016/j.waojou.2024.100984Asia-Pacific consensus on patient-centred CSU care, led by regional dermatology and allergy specialists. Cited where the site frames the patient-clinician conversation and the path to specialist care.
  3. Yong SS, Robinson S, Kwan Z, et al. Psychological well-being, quality of life and patient satisfaction among adults with chronic spontaneous urticaria in a multi-ethnic Asian population. Psychology, Health & Medicine. 2022. doi:10.1080/13548506.2022.2029914Regional (multi-ethnic Asian) evidence for the psychological and quality-of-life burden of CSU. Cited alongside refs 3 and 4 where the site discusses the emotional weight of the condition. From the campaign reference list.

Further evidence cited on this site

  1. Wagner N, Zink A, Hell K, et al. Patients with chronic urticaria remain largely undertreated: Results from the DERMLINE online survey. Dermatology and Therapy. 2021;11(3):1027-1039. doi:10.1007/s13555-021-00537-5Cited where the site notes that standard antihistamine doses do not fully control symptoms for many patients. From the campaign reference list.
  2. Friedman A, Kwatra SG, Yosipovitch G. A practical approach to diagnosing and managing chronic spontaneous urticaria. Dermatology and Therapy. 2024;14(6):1371-1387.Cited where the site discusses stepping through personalised options with a specialist when first-line relief stops working. From the campaign reference list.
  3. Weller K, Winders T, McCarthy J, et al. Urticaria Voices: Real-world experience of patients living with chronic spontaneous urticaria. Dermatology and Therapy. 2025;15:747-761.Cited where the site frames preparation and clear communication as the lever for a better consultation. From the campaign reference list.
  4. Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63(6):777-780.The UAS7 urticaria activity score. Cited on the Symptom Checker methodology note as the clinical construct behind the frequency question. Supplementary source, [MLR-PENDING] verification.
  5. Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-Q2oL). Allergy. 2005;60(8):1073-1078.The CU-Q2oL quality-of-life instrument. Cited on the Symptom Checker methodology note behind the sleep and daily-life questions. Supplementary source, [MLR-PENDING] verification.
  6. Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. Journal of Allergy and Clinical Immunology. 2014;133(5):1365-1372.The UCT urticaria control test. Cited on the Symptom Checker methodology note behind the treatment-response and control questions. Supplementary source, [MLR-PENDING] verification.
How references are used on this site. Numbered superscripts [1] appear next to factual clinical claims and link back to this page. Clicking a citation scrolls to the corresponding entry. All claims on the site are framed as educational and explicitly direct readers to consult a qualified healthcare professional for any medical decision. No claim on the site should be read as a diagnosis or a substitute for clinical care.